首页> 美国卫生研究院文献>Journal of Cerebral Blood Flow Metabolism >Hyperglycemia in aneurysmal subarachnoid hemorrhage: a potentially modifiable risk factor for poor outcome
【2h】

Hyperglycemia in aneurysmal subarachnoid hemorrhage: a potentially modifiable risk factor for poor outcome

机译:动脉瘤性蛛网膜下腔出血的高血糖:不良预后的潜在危险因素

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Hyperglycemia after aneurysmal subarachnoid hemorrhage (aSAH) occurs frequently and is associated with delayed cerebral ischemia (DCI) and poor clinical outcome. In this review, we highlight the mechanisms that cause hyperglycemia after aSAH, and we discuss how hyperglycemia may contribute to poor clinical outcome in these patients. As hyperglycemia is potentially modifiable with intensive insulin therapy (IIT), we systematically reviewed the literature on IIT in aSAH patients. In these patients, IIT seems to be difficult to achieve in terms of lowering blood glucose levels substantially without an increased risk of (serious) hypoglycemia. Therefore, before initiating a large-scale randomized trial to investigate the clinical benefit of IIT, phase II studies, possibly with the help of cerebral blood glucose monitoring by microdialysis, will first have to improve this therapy in terms of both safety and adequacy.
机译:动脉瘤性蛛网膜下腔出血(aSAH)后高血糖症频繁发生,并与延迟性脑缺血(DCI)和不良的临床预后相关。在这篇综述中,我们重点介绍了aSAH后引起高血糖的机制,并讨论了高血糖如何导致这些患者不良的临床预后。由于高血糖可能通过强化胰岛素治疗(IIT)得以改善,因此我们系统地回顾了有关SAAH患者IIT的文献。在这些患者中,很难在实质上降低血糖水平而不增加(严重)低血糖的风险的情况下实现IIT。因此,在开始大规模的随机试验以研究IIT的临床益处之前,II期研究(可能借助微透析监测脑血糖)将首先必须在安全性和充分性方面改善该疗法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号